Industry Updates
Genentech Shares New Evrysdi Data on Improved Motor Function and Survival in Babies with SMA Type 1
Genentech, a member of the Roche Group, has shared new 2-year data from Part 2 of FIREFISH, a Phase 2/3 global study evaluating Evrysdi (risdiplam) […]
Read More ›Biogen Shares New Spinraza Data Exploring Opportunities to Improve Outcomes for SMA Patients
Biogen has shared new data from the Spinraza (nusinersen) clinical development program aimed at optimizing outcomes for people with SMA and advancing understanding of the […]
Read More ›Scholar Rock Community Statement on TOPAZ 12-Month Topline Data
Scholar Rock provided the below community statement on data for apitegromab (SRK-015) following the distribution of this company press release. Dear Members of the SMA […]
Read More ›Community Statement from Genentech
Dear SMA Community, Based on our commitment to the SMA community to provide transparent, timely updates related to our medicines, we are writing to share […]
Read More ›Community Statement from Novartis Gene Therapies
Dear Cure SMA Community, Novartis Gene Therapies is committed to patient safety and the ongoing monitoring of adverse events as it relates to the use […]
Read More ›- « Previous
- 1
- …
- 5
- 6
- 7